Abcuro presented initial results from a Phase 1 open label trial of ABC008 in IBM at the American

In November 2021, Abcuro presented initial results from a Phase 1 open label trial of ABC008 in IBM at the American College of Rheumatology Convergence 2021.An updated dataset was presented at GCOM 2022. The trial demonstrated potent depletion of KLRG1+ T cells in patients with IBM, indicating the potential efficacy of ABC008 in reducing disease activity. In cancer, inhibiting KLRG1, an inhibitory immune checkpoint, can activate highly cytotoxic T and NK cells, leveraging their potent anti−tumor activity.Abcuro is advancing ABC015, a KLRG1−blocking antibody, through preclinical development for immuneoncology applications.ABC015 aims to unleash the antitumor potential of T and NK cells, providing a novel approach to cancer therapy.